1.An Unusual Case of Spontaneous Remission of Hodgkin's Disease after a Single Cycle of COPP-ABV Chemotherapy Followed by Infectious Complications.
Seungmin BANG ; June Won CHEONG ; Woo Ick YANG ; Jee Sook HAHN
Yonsei Medical Journal 2005;46(3):425-430
Advanced Hodgkin's disease is usually treated with six or more cycles of combination chemotherapy. Spontaneous regression of the cancer is very rarely reported in patients with Hodgkin's disease. We present an unusual case of a patient with Hodgkin's disease who experienced complete remission with a single cycle of chemotherapy, followed by pneumonia. The case was a 36-year-old man diagnosed with stage IVB mixed cellularity Hodgkin's disease in November 2000. After treatment with one cycle of COPP-ABV (cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine) chemotherapy without bleomycin, the patient developed interstitial pneumonia and was cared in the intensive care unit (ICU) for two months. Follow-up chest computerized tomography (CT), performed during the course of ICU care, revealed markedly improved mediastinal lymphomatous lesions. Furthermore, follow-up whole body CT and 18-fluorodeoxyglucose positron emission tomography showed complete disappearance of the lymphomatous lesions. Four years later, the patient is well and without relapse. This report is followed by a short review of the literature on spontaneous regression of Hodgkin's disease. To the best of our knowledge, this is the first case report of spontaneous remission of Hodgkin's disease in Korea.
Adult
;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
;
Bleomycin/*administration & dosage
;
Cyclophosphamide/*administration & dosage
;
Doxorubicin/*administration & dosage
;
Hodgkin Disease/*complications/*drug therapy
;
Humans
;
Male
;
Pneumonia/*complications
;
Prednisone/*administration & dosage
;
Procarbazine/*administration & dosage
;
Remission, Spontaneous
;
Vinblastine/*administration & dosage
;
Vincristine/*administration & dosage
2.The efficacy of aspartate aminotransferase-to-platelet ratio index for assessing hepatic fibrosis in childhood nonalcoholic steatohepatitis for medical practice.
Earl KIM ; Yunkoo KANG ; Seungmin HAHN ; Mi Jung LEE ; Young Nyun PARK ; Hong KOH
Korean Journal of Pediatrics 2013;56(1):19-25
PURPOSE: Childhood obesity is associated with nonalcoholic fatty liver disease (NAFLD), and it has become one of the most common causes of childhood chronic liver diseases which significant as a cause of liver related mortality and morbidity in children in the United States. The development of simpler and easier clinical indices for medical practice is needed to identify advanced hepatic fibrosis in childhood NAFLD instead of invasive method like liver biopsy. FibroScan and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) have been proposed as a simple and noninvasive predictor to evaluate hepatic fibrosis in several liver diseases. APRI could be a good alternative to detect pathologic change in childhood NAFLD. The purpose of this study is to validate the efficacy of APRI for assessing hepatic fibrosis in childhood NAFLD based on FibroScan. METHODS: This study included 23 children with NAFLD who underwent FibroScan. Clinical, laboratory and radiological evaluation including APRI was performed. To confirm the result of this study, 6 patients received liver biopsy. RESULTS: Factors associated with hepatic fibrosis (stiffness measurement >5.9 kPa Fibroscan) were triglyceride, AST, alanine aminotransferase, platelet count, APRI and collagen IV. In multivariate analysis, APRI were correlated with hepatic fibrosis (>5.9 kPa). In receiver operating characteristics curve, APRI of meaningful fibrosis (cutoff value, 0.4669; area under the receiver operating characteristics, 0.875) presented sensitivity of 94%, specificity of 66%, positive predictive value of 94%, and negative predictive value of 64%. CONCLUSION: APRI might be a noninvasive, simple, and readily available method for medical practice to predict hepatic fibrosis of childhood NAFLD.
Alanine Transaminase
;
Aspartate Aminotransferases
;
Aspartic Acid
;
Biopsy
;
Child
;
Collagen
;
Fatty Liver
;
Fibrosis
;
Humans
;
Liver
;
Liver Diseases
;
Multivariate Analysis
;
Obesity
;
Platelet Count
;
ROC Curve
;
Sensitivity and Specificity
;
United States
3.Trans-Radial versus Trans-Femoral Intervention for the Treatment of Coronary Bifurcations: Results from Coronary Bifurcation Stenting Registry.
Seungmin CHUNG ; Sung Ho HER ; Pil Sang SONG ; Young Bin SONG ; Joo Yong HAHN ; Jin Ho CHOI ; Sang Hoon LEE ; Yangsoo JANG ; Jung Han YOON ; Seung Jea TAHK ; Seung Jung PARK ; Seung Hyuk CHOI ; Ki Bae SEUNG ; Hyeon Cheol GWON
Journal of Korean Medical Science 2013;28(3):388-395
Trans-radial (TR) approach is increasingly recognized as an alternative to the routine use of trans-femoral (TF) approach. However, there are limited data comparing the outcomes of these two approaches for the treatment of coronary bifurcation lesions. We evaluated outcomes of TR and TF percutaneous coronary interventions (PCI) in this complex lesion. Procedural outcomes and clinical events were compared in 1,668 patients who underwent PCI for non-left main bifurcation lesions, according to the vascular approach, either TR (n = 503) or TF (n = 1,165). The primary outcome was major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR) in all patients and in 424 propensity-score matched pairs of patients. There were no significant differences between TR and TF approaches for procedural success in the main vessel (99.6% vs 98.6%, P = 0.08) and side branches (62.6% vs 66.7%, P = 0.11). Over a mean follow-up of 22 months, cardiac death or MI (1.8% vs 2.2%, P = 0.45), TLR (4.0% vs 5.2%, P = 0.22), and MACE (5.2% vs 7.0%, P = 0.11) did not significantly differ between TR and TF groups, respectively. These results were consistent after propensity score-matched analysis. In conclusion, TR PCI is a feasible alternative approach to conventional TF approaches for bifurcation PCI (clinicaltrials.gov number: NCT00851526).
Aged
;
Angioplasty, Balloon, Coronary/adverse effects/*methods
;
Coronary Angiography
;
Coronary Stenosis/mortality/radiography/*therapy
;
Coronary Vessels/radiography/surgery
;
*Drug-Eluting Stents
;
Female
;
Follow-Up Studies
;
Hemorrhage/etiology
;
Humans
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Myocardial Infarction/etiology
;
Myocardial Revascularization
;
Proportional Hazards Models
;
Registries